Advertisement
Singapore markets closed

  • Straits Times Index

    3,314.14
    +8.12 (+0.25%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • Dow

    39,150.33
    +15.53 (+0.04%)
     

  • Nasdaq

    17,689.36
    -32.24 (-0.18%)
     

  • Bitcoin USD

    61,048.45
    -3,327.81 (-5.17%)
     

  • CMC Crypto 200

    1,262.09
    -47.63 (-3.64%)
     

  • FTSE 100

    8,276.75
    +39.03 (+0.47%)
     

  • Gold

    2,340.10
    +8.90 (+0.38%)
     

  • Crude Oil

    80.71
    -0.02 (-0.02%)
     

  • 10-Yr Bond

    4.2650
    +0.0080 (+0.19%)
     

  • Nikkei

    38,804.65
    +208.18 (+0.54%)
     

  • Hang Seng

    18,027.71
    -0.81 (-0.00%)
     

  • FTSE Bursa Malaysia

    1,589.66
    -0.71 (-0.04%)
     

  • Jakarta Composite Index

    6,889.17
    +9.19 (+0.13%)
     

  • PSE Index

    6,272.46
    +113.98 (+1.85%)
     

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks Equity Research
·2-min read

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why This 1 Growth Stock Should Be On Your Watchlist

Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

ADVERTISEMENT

United Therapeutics (UTHR)

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.

UTHR boasts a Growth Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 24.3% year-over-year for 2024, while Wall Street anticipates its top line to improve by 16.7%.

Eight analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $1.16 to $24.62 per share for 2024. UTHR boasts an average earnings surprise of 12.4%.

On a historic basis, United Therapeutics has generated cash flow growth of 10.7%, and is expected to report cash flow expansion of 33.3% this year.

With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, UTHR should be on investors' short lists.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

United Therapeutics Corporation (UTHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research